碳青霉烯类抗生素的发展与展望(3)
[11]Mouton JW，Touzw DJ，Horrevorts AM，et al. Comparative pharmacokinetics of the carbapenems：Clinical implications[J].Clin Pharmacokinet，2000，39(3)：185-201.
[12]杜贯涛，刘广军. 多尼培南药理作用与临床应用[J].医药导报，2009，28(10)：1324-1326.
[13]Horiuchi M，Kimura M，Tokumura M，et al. Absence of convulsive liability of doripenem， a new carbapenem antibiotic，in comparison with beta-lactam antibiotics[J].Toxicol，2006，222(1-2)：114-124.
[14]Fuchs PC，Barry AL，Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical center[J].Antimicrob Agents Chemother，2001，45(6)：1915-1918.
[15]Panknch GA，Davies TA，Jacobs MR，et al. Antipeneumococoal activity of ertapenem (MK-0826) compared to those other agents[J].Antimicrob Agents chemother，2002，46(1)：42-46.
[16]张文君，吴文芳，冯小龙. 新型口服碳青霉烯类抗菌药物——泰吡培南酯[J].河北医药，2010，32(18)：2596-2599.
[17]Koga T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa[J].Antimicrob Agents Chemother，2008，52(8)：2849-2854.
(收稿日期：2011-05-03), 百拇医药(董耘婷 张永信)
[12]杜贯涛，刘广军. 多尼培南药理作用与临床应用[J].医药导报，2009，28(10)：1324-1326.
[13]Horiuchi M，Kimura M，Tokumura M，et al. Absence of convulsive liability of doripenem， a new carbapenem antibiotic，in comparison with beta-lactam antibiotics[J].Toxicol，2006，222(1-2)：114-124.
[14]Fuchs PC，Barry AL，Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical center[J].Antimicrob Agents Chemother，2001，45(6)：1915-1918.
[15]Panknch GA，Davies TA，Jacobs MR，et al. Antipeneumococoal activity of ertapenem (MK-0826) compared to those other agents[J].Antimicrob Agents chemother，2002，46(1)：42-46.
[16]张文君，吴文芳，冯小龙. 新型口服碳青霉烯类抗菌药物——泰吡培南酯[J].河北医药，2010，32(18)：2596-2599.
[17]Koga T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa[J].Antimicrob Agents Chemother，2008，52(8)：2849-2854.
(收稿日期：2011-05-03), 百拇医药(董耘婷 张永信)